PD-1 / PD-L1 monoclonal antibody

DRUG4 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Liaoning Cancer Hospital & Institute, Repertoire Immune Medicines, Suzhou BlueHorse Therapeutics Co., Ltd.

Conditions

Advanced Breast CancerAdvanced Malignant Solid TumorGastric / Gastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer

Phase 1

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

RecruitingNCT07293754

Repertoire Immune MedicinesAdvanced Malignant Solid Tumor

Start: 2025-12-12End: 2029-04-15Target: 150Updated: 2026-02-17

Phase 2

LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Not yet recruitingNCT07444437

Suzhou BlueHorse Therapeutics Co., Ltd.Non-Small Cell Lung Cancer

Start: 2026-02-26End: 2028-12-31Target: 45Updated: 2026-03-03

Phase 4

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

Not yet recruitingNCT07161453

Liaoning Cancer Hospital & InstituteGastric / Gastroesophageal Junction Adenocarcinoma

Start: 2025-09-30End: 2027-12-31Target: 500Updated: 2025-09-08

Unknown Phase

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

RecruitingNCT06776861

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Breast Cancer

Start: 2024-09-24End: 2028-09-10Target: 150Updated: 2025-01-15